| Associated factors | Number | Lipodystrophy | Odds ratio | P | |
| Yes N (%) | No N (%) | (IC) | |||
| Age (years) ≤10 >10 |
156 167 |
15 (9.6) 30 (18) |
141 (90.4) 137 (82) |
1 0.5 (0.3 - 1) |
0.005 |
| Sex Female Male |
161 162 |
17 (10.6) 28 (17.3) |
144 (89.4) 134 (82.7) |
1 1 (0.9 - 1.1)) |
0.042 |
| Clinical stage |
|
|
|
|
|
| 1 | 2 | 1 (50) | 1 (50) | 1 |
|
| 2 | 62 | 3 (4.8) | 59 (95.2) | 7.5 (5.2 - 9.4) | 0.5 |
| 3 | 233 | 39 (16.7) | 194 (83.3) | 0.3 (0.2 - 0.8) | 0.001 |
| 4 | 26 | 2 (7.7) | 24 (92.3) | 2.4 (0.9 - 5.5) | 0.06 |
| Treatment duration ARV |
|
|
|
|
|
| <60 | 189 | 12 (6.3) | 177 (93.7) | 1 |
|
| >60 | 134 | 33 (24.6) | 101 (75.4) | 0.4 (0.2 - 0.7) | <0.001 |
| Initial treatment regimen |
|
|
|
|
|
| AZT− | 145 | 36 (24.8) | 109 (75.2) | 1 |
|
| AZT+ | 178 | 9 (5) | 169 (95) | 6.3 (0.2 - 8.2) | 0.41 |
| D4T− | 184 | 10 (5.4) | 174 (94.6) | 1 |
|
| D4T+ | 139 | 35 (25.2) | 104 (74.8) | 0.2 (0.1 - 0.3) | <0.001 |
| Lopi/rt− | 271 | 33 (12.2) | 238 (87.8) | 1 |
|
| Lopi/rt+ | 52 | 12 (23) | 40 (77) | 0.4 (0.2 - 0.6) | 0.06 |